New York State Common Retirement Fund Raises Position in IDEAYA Biosciences, Inc. $IDYA

New York State Common Retirement Fund lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 21.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 488,956 shares of the company’s stock after acquiring an additional 87,264 shares during the quarter. New York State Common Retirement Fund’s holdings in IDEAYA Biosciences were worth $13,304,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new stake in IDEAYA Biosciences in the 2nd quarter valued at approximately $61,000. CWM LLC lifted its holdings in shares of IDEAYA Biosciences by 33.0% in the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock valued at $66,000 after buying an additional 782 shares during the period. Daiwa Securities Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of IDEAYA Biosciences by 39.1% in the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after buying an additional 940 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of IDEAYA Biosciences by 59.1% in the second quarter. Osaic Holdings Inc. now owns 7,443 shares of the company’s stock valued at $148,000 after buying an additional 2,764 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IDYA shares. JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group increased their price target on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, October 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. New Street Research set a $30.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Finally, BTIG Research reiterated a “buy” rating and set a $62.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.60.

IDEAYA Biosciences Trading Up 5.8%

Shares of IDYA opened at $34.06 on Tuesday. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $39.28. The stock has a market cap of $2.99 billion, a P/E ratio of -18.31 and a beta of 0.10. The company has a 50-day moving average of $34.99 and a two-hundred day moving average of $29.81.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, beating the consensus estimate of ($0.12) by $1.45. The business had revenue of $207.83 million during the quarter, compared to analyst estimates of $59.98 million. As a group, analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.